CA2234641A1 - Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique - Google Patents

Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique Download PDF

Info

Publication number
CA2234641A1
CA2234641A1 CA002234641A CA2234641A CA2234641A1 CA 2234641 A1 CA2234641 A1 CA 2234641A1 CA 002234641 A CA002234641 A CA 002234641A CA 2234641 A CA2234641 A CA 2234641A CA 2234641 A1 CA2234641 A1 CA 2234641A1
Authority
CA
Canada
Prior art keywords
aryl
phenyl
group
hydrogen
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002234641A
Other languages
English (en)
Inventor
Charles G. Caldwell
William K. Hagmann
Malcolm Maccoss
Shrenik K. Shah
Kothandaraman Shankaran
Karla L. Furman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605162.8A external-priority patent/GB9605162D0/en
Priority claimed from GBGB9605700.5A external-priority patent/GB9605700D0/en
Application filed by Individual filed Critical Individual
Publication of CA2234641A1 publication Critical patent/CA2234641A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings

Abstract

L'invention porte sur des composés de formule (I) et leurs sels pharmacocompatibles s'avérant utiles pour le traitement de maladies et affections dues à la synthase de l'oxyde nitrique et notamment de troubles neurodégénératifs, de troubles de la motilité gastro-intestinale et d'inflammations. Ces maladies et affections englobent l'hypotension, le choc septique, le syndrome de choc toxique, l'hémodialyse, le traitement de cancéreux par l'IL-2, la cachexie, l'immuno-suppression accompagnant les thérapies de transplantation, les troubles à caractère auto-immunitaire ou inflammatoire tels que les coups de soleil, l'eczéma ou le psoriasis et les troubles respiratoires tels que la bronchite, l'asthme, les lésions pulmonaires dues à des oxydants et l'emphysème pulmonaire, la glomérulonéphrite, les resténoses, les séquelles inflammatoires d'infections virales, les myocardites, l'insuffisance cardiaque, l'athérosclérose, l'arthrose, la polyarthrite rhumatoïde, l'arthrite aiguë suppurée, les troubles intestinaux chroniques ou inflammatoires, la rectocolite hémorragique, la maladie de Crohn, le lupus érythémateux systémique, des troubles oculaires tels que le glaucome, la rétinite ou l'uvéite, les diabètes de type 1, le diabète sucré insulinodépendant, et la fibrose kystique du pancréas.
CA002234641A 1995-11-01 1996-10-28 Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique Abandoned CA2234641A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US717295P 1995-11-01 1995-11-01
US60/007,172 1995-11-01
US901295P 1995-12-21 1995-12-21
US60/009,012 1995-12-21
GBGB9605162.8A GB9605162D0 (en) 1996-03-12 1996-03-12 Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GBGB9605700.5A GB9605700D0 (en) 1996-03-19 1996-03-19 Hexahydro-5-imino,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9605162.8 1996-03-19
GB9605700.5 1996-03-19
PCT/US1996/017447 WO1997016430A1 (fr) 1995-11-01 1996-10-28 Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique

Publications (1)

Publication Number Publication Date
CA2234641A1 true CA2234641A1 (fr) 1997-05-09

Family

ID=27451425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002234641A Abandoned CA2234641A1 (fr) 1995-11-01 1996-10-28 Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique

Country Status (5)

Country Link
EP (1) EP0861238A4 (fr)
JP (1) JP3188715B2 (fr)
AU (1) AU700078B2 (fr)
CA (1) CA2234641A1 (fr)
WO (1) WO1997016430A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2136661C1 (ru) * 1993-10-21 1999-09-10 Джи Ди Сирл энд Ко. Амидинопроизводные, их применение и фармацевтическая композиция
WO1996033175A1 (fr) * 1995-04-20 1996-10-24 G.D. Searle & Co. Agents amidino cycliques utiles en tant qu'inhibiteurs de synthase de l'oxyde nitrique
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
US6489323B1 (en) 1998-06-10 2002-12-03 G.D. Searle & Co. Heterobicyclic and tricyclic nitric oxide synthase inhibitors
SE9901530D0 (sv) * 1999-04-28 1999-04-28 Astra Pharma Prod Novel compounds
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
EP2085400A1 (fr) 2008-01-29 2009-08-05 Sanofi-Aventis Dérivés d'hétéroarylamide oxazépinopyrimidone substitués
EP2090578A1 (fr) 2008-01-29 2009-08-19 Sanofi-Aventis Dérivés d'arylamide diazépinopyrimidone substitués pour le traitement des maladies neurodégénératives causées par une activité anormale de GSK3-beta
EP2090579A1 (fr) 2008-01-29 2009-08-19 Sanofi-Aventis Dérivés d'hétéroarylamide diazépinopyrimidone substitués
EP2085399A1 (fr) 2008-01-29 2009-08-05 Sanofi-Aventis Dérivés d'arylamide oxazépinopyrimidone substitués
EP2138488A1 (fr) 2008-06-26 2009-12-30 sanofi-aventis Dérivés de 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-ones comme inhibiteurs de GSK3-beta utiles pour le traitement de maladies neurodégénératives
EP2138493A1 (fr) 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués de pyrimidone
EP2138495A1 (fr) 2008-06-26 2009-12-30 sanofi-aventis Dérivés substitués de pyrimido[2,1-a]isoquinolin-4-one
EP2138492A1 (fr) 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués de pyrimidin-4-one
EP2138494A1 (fr) 2008-06-26 2009-12-30 Sanofi-Aventis Dérivés substitués d'alkyl pyrimidin-4-one
EP2138498A1 (fr) 2008-06-26 2009-12-30 sanofi-aventis Dérivés tricycliques substitués contre les maladies neurodégénératives
EP2138485A1 (fr) 2008-06-26 2009-12-30 sanofi-aventis Dérivés substitués de N-oxyde pyrazine
KR20220105661A (ko) * 2019-11-26 2022-07-27 길리애드 사이언시즈, 인코포레이티드 Mcl1 억제제를 제조하기 위한 방법 및 중간체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
US3444169A (en) * 1966-01-17 1969-05-13 American Cyanamid Co Process for 11 - aminodibenz(b,f)(1,4)oxazepines and analogous thiazepines
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
AT355025B (de) * 1974-11-29 1980-02-11 Sandoz Ag Verfahren zur herstellung neuer 5-amino-7- phenyl-2,3-dihydro-1h-1,4-diazepine
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
RU2136661C1 (ru) * 1993-10-21 1999-09-10 Джи Ди Сирл энд Ко. Амидинопроизводные, их применение и фармацевтическая композиция
US5629322A (en) * 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase

Also Published As

Publication number Publication date
JP3188715B2 (ja) 2001-07-16
WO1997016430A1 (fr) 1997-05-09
AU7528796A (en) 1997-05-22
JPH11501327A (ja) 1999-02-02
EP0861238A1 (fr) 1998-09-02
EP0861238A4 (fr) 2000-03-01
AU700078B2 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
US6372733B1 (en) Hexahydro-5-imino-1,4-1,4-thiazepine derivatives as inhibitors of nitric oxide synthases
CA2234641A1 (fr) Derives de l'hexahydro-5-imino-1,4-heteroazepine inhibiteurs des synthases de l'oxyde nitrique
US5629322A (en) Cyclic amidine analogs as inhibitors of nitric oxide synthase
EP0054951B1 (fr) Dibenzo(b,f)(1,4)oxazépines, leur procédé de préparation et les compositions pharmaceutiques les contenant
KR100305989B1 (ko) 파르네실-단백질트랜스퍼라제의억제제및이를포함하는약제학적조성물
Srivastava et al. Synthesis and biological evaluation of 4-thiazolidinone derivatives as potential antimycobacterial agents
WO1996014842A1 (fr) Heterocycles a substitutions utilises en tant qu'inhibiteurs de la synthetase d'oxyde nitrique
EP2252596B1 (fr) Pro-médicaments de cystéine et de cystine pour traiter la schizophrénie et réduire les addictions aux médicaments
JP4637584B2 (ja) 新規なラクタムおよびその使用
MX2008013137A (es) Compuestos organicos.
WO2008079836A2 (fr) Inhibiteurs macrocycliques du facteur viia utiles en tant qu'anticoagulants
EP2374454B1 (fr) Dérivés d'hémiasterline et leurs utilisations pour le traitement du cancer
CA2097465A1 (fr) Pyrazinoindoles
US7351721B2 (en) Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
CA2721433A1 (fr) Bioisosteres de la cysteine et de la cystine destines a traiter la schizophrenie et a soulager les etats de manque
CA2218360A1 (fr) Inhibiteurs de la synthase d'oxyde nitrique derives des amidines cycliques
AU2002332640B2 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
EP1664088A2 (fr) Derives d'hemiasterline et utilisations de ces derives
IE840927L (en) 1,5-benzothiazepines
AU2002332640A1 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2001055118A1 (fr) Derives heterocycliques condenses au benzene et medicaments contenant ceux-ci comme ingredients actifs
NZ258889A (en) 3-alkylamino-1,5-benzoxazepin- (and benzothiazepin-) 4-one derivatives and pharmaceutical compositions
HU208420B (en) Process for producing compounds with analgesic activity for the central nerve systhem and process for producing pharmaceutical activity containing them
GB2065105A (en) Dibenzazepines
GB2307911A (en) Substituted saturated aza heterocycle inhibitors of nitric oxide synthase

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead